2022
DOI: 10.1186/s12943-022-01552-6
|View full text |Cite
|
Sign up to set email alerts
|

CRISPR based therapeutics: a new paradigm in cancer precision medicine

Abstract: Background Clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated protein (Cas) systems are the latest addition to the plethora of gene-editing tools. These systems have been repurposed from their natural counterparts by means of both guide RNA and Cas nuclease engineering. These RNA-guided systems offer greater programmability and multiplexing capacity than previous generation gene editing tools based on zinc finger nucleases and transcription activator like effect… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
18
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 22 publications
(18 citation statements)
references
References 126 publications
0
18
0
Order By: Relevance
“…At the same time the benefits of Precision/Personalized Medicine and the major obstacles for all stakeholders involved are summarized as well as specific solutions are provided. Knowledge and perception of Medical and Pharmacy students towards Pharmacogenomics and Genetics is also presented [6, 8–10, 22, 27–29, 33, 34, 45, 51, 53–55, 59, 67, 74–77, 81–83, 85–107, 112, 113, 121].…”
Section: Resultsmentioning
confidence: 99%
“…At the same time the benefits of Precision/Personalized Medicine and the major obstacles for all stakeholders involved are summarized as well as specific solutions are provided. Knowledge and perception of Medical and Pharmacy students towards Pharmacogenomics and Genetics is also presented [6, 8–10, 22, 27–29, 33, 34, 45, 51, 53–55, 59, 67, 74–77, 81–83, 85–107, 112, 113, 121].…”
Section: Resultsmentioning
confidence: 99%
“…Research on gene silencing is progressing with the application of CRISPR interference, which physically inhibits the transcription process without altering the DNA sequence 48 . While various viral and non‐viral vectors that can carry CRISPR‐Cas components to different target organs are under development and are expected to contribute to individualization of cancer precision medicine, 49 enhancer regions of the ITPR3 gene might be targeted by these techniques.…”
Section: Discussionmentioning
confidence: 99%
“…However, features of transcription factor interactions with DNA and co-factors—elements of disorder or ‘fuzziness’ without structured binding pockets [ 24 , 25 ]—limited progress in the field for decades, and there was a general consensus that transcription was undruggable. Recent developments that promise to reverse this perspective include new knowledge of intrinsically disordered proteins, cellular thermal shift assays to interrogate target engagement, binding-focused drug screening methodologies, proteolysis targeting chimera-based therapeutics, and CRISPR-directed transcriptional interventions [ 26 , 27 ]. In the area of medical oncology in particular, numerous therapeutics that target transcription factor activity are currently under development or have already entered clinical trials [ 28 ].…”
Section: Discussionmentioning
confidence: 99%